References
- Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. doi:https://doi.org/10.1056/NEJMra1001389
- Kotiyal S, Bhattacharya S. Breast cancer stem cells, EMT and therapeutic targets. Biochem Biophys Res Commun. 2014;453(1):112–6. doi:https://doi.org/10.1016/j.bbrc.2014.09.069
- Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84. doi:https://doi.org/10.1038/s41580-018-0080-4
- Almendro V, Kim HJ, Cheng Y-K, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014;74(5):1338–48. doi:https://doi.org/10.1158/0008-5472.CAN-13-2357-T
- Hao Y, Baker D, Dijke PT. TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. IJMS. 2019;20(11):2767. doi:https://doi.org/10.3390/ijms20112767
- Katsuno Y, Lamouille S, Derynck R. TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2013;25(1):76–84. doi:https://doi.org/10.1097/CCO.0b013e32835b6371
- Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):201–12. doi:https://doi.org/10.1007/s10911-010-9177-x
- Prasad S, Tyagi A. Historical spice as a future drug: therapeutic potential of piperlongumine. Curr Pharm Des. 2016;22(27):4151–9. doi:https://doi.org/10.2174/1381612822666160601103027
- Jin H-O, Lee Y-H, Park J-A, Lee H-N, Kim J-H, Kim J-Y, Kim BRa, Hong S-E, Kim H-A, Kim E-K, et al. Piperlongumine induces cell death through ROS-mediated CHOP activation and potentiates TRAIL-induced cell death in breast cancer cells. J Cancer Res Clin Oncol. 2014;140(12):2039–46. doi:https://doi.org/10.1007/s00432-014-1777-1
- Park J-A, Na H-H, Jin H-O, Kim K-C. Increased expression of FosB through reactive oxygen species accumulation functions as pro-apoptotic protein in piperlongumine Treated MCF7 Breast Cancer Cells. Mol Cells. 2019;42(12):884–92. doi:https://doi.org/10.14348/molcells.2019.0088
- Liu JM, Pan F, Li L, Liu QR, Chen Y, Xiong XX, Cheng K, Yu SB, Shi Z, Yu AC-H, et al. Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation. Biochem Biophys Res Commun. 2013;437(1):87–93. doi:https://doi.org/10.1016/j.bbrc.2013.06.042
- Roh J-L, Kim EH, Park JY, Kim JW, Kwon M, Lee B-H. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget. 2014;5(19):9227–38. doi:https://doi.org/10.18632/oncotarget.2402
- Huang BK, Langford TF, Sikes HD. Using sensors and generators of H2O2 to elucidate the toxicity mechanism of piperlongumine and phenethyl isothiocyanate. Antioxid Redox Signal. 2016;24(16):924–38. doi:https://doi.org/10.1089/ars.2015.6482
- Wang J, Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther. 2008;7(12):1875–84. doi:https://doi.org/10.4161/cbt.7.12.7067
- Chen D, Ma Y, Li P, Liu M, Fang Y, Zhang J, Zhang B, Hui Y, Yin Y. Piperlongumine induces apoptosis and synergizes with doxorubicin by inhibiting the JAK2-STAT3 pathway in triple-negative breast cancer. Molecules. 2019;24(12):2338. doi:https://doi.org/10.3390/molecules24122338
- Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, Wu Q, Cao J, Sang W, Zeng L, et al. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-κB p65 subunit nuclear import. Biochem Biophys Res Commun. 2015;462(4):326–31. doi:https://doi.org/10.1016/j.bbrc.2015.04.136
- Shrivastava S, Kulkarni P, Thummuri D, Jeengar MK, Naidu VGM, Alvala M, Redddy GB, Ramakrishna S. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells . Apoptosis. 2014;19(7):1148–64. doi:https://doi.org/10.1007/s10495-014-0991-2
- Niu M, Xu X, Shen Y, Yao Y, Qiao J, Zhu F, Zeng L, Liu X, Xu K. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. Chem Biol Interact. 2015;237:66–72. doi:https://doi.org/10.1016/j.cbi.2015.05.016
- Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001; Unit 20.2. doi:https://doi.org/10.1002/0471142735.im2002s39
- Zhang F, Wang Z, Fan Y, Xu Q, Ji W, Tian R, Niu R. Elevated STAT3 signaling-mediated upregulation of MMP-2/9 confers enhanced invasion ability in multidrug-resistant breast cancer cells. Int J Mol Sci. 2015;16(10):24772–90. doi:https://doi.org/10.3390/ijms161024772
- Ren F, Tang R, Zhang X, Madushi WM, Luo D, Dang Y, Li Z, Wei K, Chen G. Overexpression of MMP family members functions as prognostic biomarker for breast cancer patients: a systemic review and meta-analysis. PLoS One. 2015;10(8):e0135544. doi:https://doi.org/10.1371/journal.pone.0135544
- Wiercinska E, Naber HP, Pardali E, van der Pluijm G, van Dam H, ten Dijke P. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Res Treat. 2011;128(3):657–66. doi:https://doi.org/10.1007/s10549-010-1147-x
- Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe?. Curr Opin Cell Biol. 2016;43:7–13. doi:https://doi.org/10.1016/j.ceb.2016.06.002
- Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39. doi:https://doi.org/10.1002/1878-0261.12017
- Law ME, Corsino PE, Jahn SC, Davis BJ, Chen S, Patel B, Pham K, Lu J, Sheppard B, Nørgaard P, et al. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene. 2013;32(10):1316–29. doi:https://doi.org/10.1038/onc.2012.138
- Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci. 2013;116:317–36. doi:https://doi.org/10.1016/B978-0-12-394311-8.00014-5
- Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. Anastasiadis PZ: A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358(1):78–85. doi:https://doi.org/10.1016/j.yexcr.2017.04.006
- Liu T, Zhang X, Shang M, Zhang Y, Xia B, Niu M, Liu Y, Pang D. Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol. 2013;107(2):188–94. doi:https://doi.org/10.1002/jso.23240
- Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62(6):1613–8.
- Mazda M, Nishi K, Naito Y, Ui-Tei K. E-cadherin is transcriptionally activated via suppression of ZEB1 transcriptional repressor by small RNA-mediated gene silencing. PLoS One. 2011;6(12):e28688doi:https://doi.org/10.1371/journal.pone.0028688
- Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9(6):582–9. doi:https://doi.org/10.1038/embor.2008.74
- Park S-M, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22(7):894–907. doi:https://doi.org/10.1101/gad.1640608
- Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010;9:179. doi:https://doi.org/10.1186/1476-4598-9-179
- Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013;73(11):3470–80.,. doi:https://doi.org/10.1158/0008-5472.CAN-12-4524-T
- Ortiz-Montero P, Londono-Vallejo A, Vernot JP. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line. Cell Commun Signal. 2017;15(1):17doi:https://doi.org/10.1186/s12964-017-0172-3
- Suarez-Carmona M, Bourcy M, Lesage J, Leroi N, Syne L, Blacher S, Hubert P, Erpicum C, Foidart J-M, Delvenne P, et al. Soluble factors regulated by epithelial-mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment. J Pathol. 2015;236(4):491–504.,. doi:https://doi.org/10.1002/path.4546
- Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2003;103(5):642–6. doi:https://doi.org/10.1002/ijc.10833
- Katsura A, Tamura Y, Hokari S, Harada M, Morikawa M, Sakurai T, Takahashi K, Mizutani A, Nishida J, Yokoyama Y, et al. ZEB1-regulated inflammatory phenotype in breast cancer cells. Mol Oncol. 2017;11(9):1241–62.,. doi:https://doi.org/10.1002/1878-0261.12098
- Jeong CH, Ryu H, Kim DH, Cheng WN, Yoon JE, Kang S, Han SG. Piperlongumine induces cell cycle arrest via reactive oxygen species accumulation and IKKβ suppression in human breast cancer cells. Antioxidants. 2019;8(11):553. doi:https://doi.org/10.3390/antiox8110553
- Harshbarger W, Gondi S, Ficarro SB, Hunter J, Udayakumar D, Gurbani D, Singer WD, Liu Y, Li L, Marto JA, et al. Structural and biochemical analyses reveal the mechanism of glutathione S-transferase pi 1 inhibition by the anti-cancer compound piperlongumine. J Biol Chem. 2017;292(1):112–20. doi:https://doi.org/10.1074/jbc.M116.750299
- Patel K, Chowdhury N, Doddapaneni R, Boakye CHA, Godugu C, Singh M. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J Pharm Sci. 2015;104(12):4417–26. doi:https://doi.org/10.1002/jps.24637
- Yao JX, Yao ZF, Li ZF, Liu YB. Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. Asian Pac J Cancer Prev. 2014;15(7):3211–7. doi:https://doi.org/10.7314/apjcp.2014.15.7.3211